渣渣机翻
位于蒂宾根的CureVac公司正在研究高压下的电晕疫苗。根据WELT AM SONNTAG(德国报纸)获得的信息，美国政府希望获得对其的专有权。德国政府正在努力防止这种情况。
据报道，在美国和德国之间，电晕危机引发了间接但切实的经济政策辩论。原因：美国总统唐纳德·特朗普(Donald Trump)试图利用高额的经济诱因，吸引从事潜在电晕疫苗研究工作的德国科学家到美国，或专门为该国购买该药。 WELT AM SONNTAG在政府圈子中听到了这一消息。
据称，这位美国总统为公司提供了大量资金，以专门确保其工作。特朗普正在竭尽全力为美国买疫苗。联邦政府说：“但只限于美国。”
根据来自WELT AM SONNTAG的信息，这两个州之间的争端与CureVac公司有关，该公司位于图宾根，与联邦拥有的保罗·埃里希疫苗和生物医学研究所合作生产这种病毒的疫苗。政府官员现在正在与CureVac进行谈判。
德国联邦卫生部发言人WELT AM SONNTAG证实：“联邦政府对在德国和欧洲也正在开发针对新型日冕病毒的疫苗和活性物质非常感兴趣。” “在这方面，政府正在与CureVac公司进行密集的谈判。”我们听到柏林政府试图让公司获得财务要约。该公司本身拒绝回答问题。
英文版 ...
The Tbingen-based company CureVac is researching a corona vaccine under high pressure. According to information aquired by WELT AM SONNTAG (German Newspaper), the US government wants to secure the exclusive rights to it. The German government is trying to prevent this.
Between the United States and Germany, the Corona crisis is reported to lead to an indirect but tangible economic policy debate. The reason: US President Donald Trump tries to lure German scientists working on a potential corona vaccine to America using high financial incentives, or to secure the drug exclusively for his country. WELT AM SONNTAG heard this in government circles.
The US president allegedly offers the company a large amount of money to secure its work exclusively. Trump is doing everything possible to get a vaccine for the United States. "But only for the USA," says the federal government.
According to information from WELT AM SONNTAG, the dispute between the two states is about the company CureVac, which is based in Tbingen and works together with the federally owned Paul Ehrlich Institute for Vaccines and Biomedical Medicines on the production of a vaccine against the virus. Government officials are now negotiating with CureVac.
"The Federal Government is very interested in the fact that vaccines and active substances against the novel corona virus are also being developed in Germany and Europe," confirmed a spokesman for the (German) Ministry of Health to WELT AM SONNTAG. "In this regard, the government is in intensive talks with the company CureVac." We hear the government in Berlin tries to keep the company with financial offers. The company itself refused to answer questions.